Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Personalized neoantigen DNA vaccine + nivolumab + ipilimumab + PROSTVAC
- Development stage
- Unknown
- Lead developer
- Washington University School of Medicine
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Electroporation, Intravenous, Subcutaneous
01
Overview
This combination therapy is a multi-modal immunotherapy regimen designed for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). It integrates four distinct components to stimulate a robust anti-tumor immune response: a personalized neoantigen DNA vaccine, the recombinant viral vaccine PROSTVAC, and the dual immune checkpoint inhibitors nivolumab (Opdivo) and ipilimumab (Yervoy). The personalized DNA vaccine, which encodes approximately 20 patient-specific mutated epitopes, is delivered via Ichor Medical Systems' TriGrid electroporation technology to prime tumor-specific T cells. PROSTVAC targets the shared prostate-specific antigen (PSA) and incorporates co-stimulatory molecules (B7.1, ICAM-1, and LFA-3) to further boost the immune response. Nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) are added to overcome immunosuppressive mechanisms within the tumor microenvironment. This strategy aims to induce a synergistic effect by combining shared antigen and neoantigen targeting with the removal of immune checkpoints.
- Other names
- Personalized neoantigen DNA vaccine + Opdivo + Yervoy + PROSTVACPersonalized polyepitope DNA vaccine + nivolumab + ipilimumab + PROSTVAC
02
Targets
CD80 (T-lymphocyte activation antigen CD80)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)ICAM1 (Intercellular Adhesion Molecule 1)CD58 (Leukocyte function-associated antigen 3)PDCD1 (Programmed cell death protein 1 receptor)PSA (Puromycin-sensitive aminopeptidase)MHC I (MHC class I})Neoantigen-specific T-cell receptor
Beyond the preview
Go deeper on Personalized neoantigen DNA vaccine + nivolumab + ipilimumab + PROSTVAC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Personalized neoantigen DNA vaccine + nivolumab + ipilimumab + PROSTVAC.